The 340B Drug Pricing Program remains a critical yet increasingly complex component of pharmacy financial strategy, with ongoing legal, regulatory, and operational pressures shaping how health systems manage compliance, eligibility, and program sustainability. As the environment continues to evolve, pharmacy leaders must balance financial reliance on the program with heightened scrutiny, changing manufacturer practices, and increasing administrative complexity. In this session, explore the current state of the 340B landscape and the strategies health systems are using to protect program integrity while adapting to emerging challenges.

Join a healthcare and legal industry thought leader with expertise in both pharmacy operations and regulatory frameworks as they provide an updated perspective on the future of the 340B program and its implications for IDN pharmacy strategy.

Learning Objectives:
1. Identify current legal, regulatory, and operational trends impacting the 340B program.
2. Analyze risks and challenges associated with maintaining program compliance and financial sustainability.
3. Evaluate strategies health systems are using to adapt to increasing scrutiny and complexity in 340B operations.
4. Assess potential future scenarios for the 340B program and their implications for pharmacy leadership planning.